Verrica Pharmaceuticals Inc
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and sale of medications for the treatment of skin diseases in the United States. The company's product pipeline includes YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for treating external genital warts, as well as for mo… Read more
Verrica Pharmaceuticals Inc (VRCA) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.568x
Based on the latest financial reports, Verrica Pharmaceuticals Inc (VRCA) has a cash flow conversion efficiency ratio of -0.568x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($9.69 Million) by net assets ($-17.04 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Verrica Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Verrica Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Verrica Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Verrica Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sri panwa Hospitality Real Estate Investment Trust
BK:SRIPANWA
|
0.011x |
|
Chengdu PUTIAN Telecommunications Cable Company Limited
F:CUEH
|
-0.029x |
|
PJ Electronics Co. Ltd
KQ:006140
|
0.084x |
|
Guyoung Technology Co. Ltd
KQ:053270
|
0.066x |
|
Maniker F & G Co. Ltd
KQ:195500
|
0.024x |
|
Hermès International Société en commandite par actions
BE:HMI
|
N/A |
|
Vroom, Inc. Common Stock
PINK:VRM
|
0.155x |
|
Jeilin Technology Co., Ltd.
TWO:8102
|
-0.142x |
Annual Cash Flow Conversion Efficiency for Verrica Pharmaceuticals Inc (2016–2024)
The table below shows the annual cash flow conversion efficiency of Verrica Pharmaceuticals Inc from 2016 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-9.86 Million | $-60.93 Million | 6.179x | +416.56% |
| 2023-12-31 | $19.76 Million | $-38.58 Million | -1.952x | -319.00% |
| 2022-12-31 | $40.03 Million | $-18.65 Million | -0.466x | +44.93% |
| 2021-12-31 | $32.60 Million | $-27.58 Million | -0.846x | +7.62% |
| 2020-12-31 | $32.99 Million | $-30.21 Million | -0.916x | -117.23% |
| 2019-12-31 | $65.02 Million | $-27.41 Million | -0.422x | -110.92% |
| 2018-12-31 | $89.43 Million | $-17.87 Million | -0.200x | -130.71% |
| 2017-12-31 | $-7.04 Million | $-4.58 Million | 0.651x | +7.64% |
| 2016-12-31 | $-2.66 Million | $-1.61 Million | 0.605x | -- |